Targeting cyclin D1 in non-small cell lung cancer and mesothelioma cells by antisense oligonucleotides.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Anticancer Research

• Publication date

  2011-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 22110187
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells

  2011cited by this paper
• Cell cycle, CDKs and cancer: a changing paradigm

  2009cited by this paper
• Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide.

  2008cited by this paper
• Multiple levels of cyclin specificity in cell-cycle control

  2007cited by this paper
• Degradation of cyclin D3 independent of Thr-283 phosphorylation

  2006cited by this paper
• Antisense to Cyclin D1 Inhibits Vascular Endothelial Growth Factor–Stimulated Growth of Vascular Endothelial Cells: Implication of Tumor Vascularization

  2006cited by this paper
• Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.

  2005cited by this paper
• Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

  2005cited by this paper
• Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis

  2005cited by this paper
• Specific Chemopreventive Agents Trigger Proteasomal Degradation of G1 Cyclins: Implications for Combination Therapy

  2004cited by this paper
• Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

  2004cited by this paper
• The Retinoblastoma Protein and Cell Cycle Control Review

  2004cited by this paper
• Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.

  2004cited by this paper
• Synthetic approaches to indolo[6,7-a]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors.

  2004cited by this paper
• Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.

  2003cited by this paper
• Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.

  2003cited by this paper
• Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors.

  2003cited by this paper
• Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.

  2003cited by this paper
• Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms

  2003cited by this paper
• Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells.

  2003cited by this paper
• Small-molecule cyclin-dependent kinase modulators

  2003cited by this paper
• Cyclin D1 Splice Variants

  2003cited by this paper
• Searching for selective cyclin-dependent kinase inhibitors to target the retinoblastoma/p16 cancer gene pathway.

  2001cited by this paper
• Cinnamaldehydes inhibit cyclin dependent kinase 4/cyclin D1.

  2000cited by this paper
• Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells.

  1999cited by this paper
• Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas.

  1999cited by this paper
• Sequence and structure-based prediction of eukaryotic protein phosphorylation sites.

  1999cited by this paper
• Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum.

  1998cited by this paper
• Inhibition of Cell Proliferation in Head and Neck Squamous Cell Carcinoma Cell Lines with Antisense Cyclin D1

  1998cited by this paper
• Antisense to Cyclin Dl Inhibits the Growth and Tumorigenicity of Human Colon Cancer Cells1

  1997cited by this paper
• Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism.

  1997cited by this paper
• Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells.

  1997cited by this paper
• Antisense oligodeoxynucleotides targeted against different regions of cyclin D1 mRNA may exert different inhibitory effects on cell growth and gene expression.

  1996cited by this paper
• Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation.

  1996cited by this paper
• Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer.

  1995cited by this paper
• The retinoblastoma protein and cell cycle control.

  1995cited by this paper
• Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer.

  1994cited by this paper
• CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1.

  1994cited by this paper
• Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4.

  1993cited by this paper
• Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein.

  1993cited by this paper
• Functional interactions of the retinoblastoma protein with mammalian D-type cyclins.

  1993cited by this paper
• Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins.

  1992cited by this paper

• BMP and activin membrane-bound inhibitor regulate connective tissue growth factor controlling mesothelioma cell proliferation

  2022cites this paper
• Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma

  2022cites this paper
• Analysis of CCND1 protein and circulatory antioxidant enzyme activity association in oral squamous cell carcinoma

  2021cites this paper
• Quercetin reduces cyclin D1 activity and induces G1 phase arrest in HepG2 cells

  2016cites this paper
• Gene therapy in management of lung cancer

  2015cites this paper
• [Modern Nanomedicine in Treatment of Lung Carcinomas].

  2015cites this paper
• A molecular targeting against nuclear factor-κB, as a chemotherapeutic approach for human malignant mesothelioma

  2014cites this paper
• MicroRNA-545 Suppresses Cell Proliferation by Targeting Cyclin D1 and CDK4 in Lung Cancer Cells

  2014cites this paper
• A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS

  2013cites this paper
• CCND1 G870A polymorphism interaction with cigarette smoking increases lung cancer risk: meta-analyses based on 5008 cases and 5214 controls

  2013cites this paper
• CD146 and insulin‐like growth factor 2 mRNA‐binding protein 3 predict prognosis of asbestos‐induced rat mesothelioma

  2013cites this paper
• Prognostic value of cyclin D1 expression in tumor-free surgical margins in head and neck squamous cell carcinomas

  2013cites this paper
• CCND1 G870A polymorphism interaction with cigarette smoking increases lung cancer risk: meta-analyses based on 5008 cases and 5214 controls

  2013cites this paper
• MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma cells.

  2012cites this paper
• Yes is a central mediator of cell growth in malignant mesothelioma cells.

  2012cites this paper
• Lack of association of the cyclin D1 G870A variation with oral carcinoma risk: Evidence from 2,404 subjects

  2012cites this paper
• Cyclin D1 G870A Polymorphism is a Risk Factor for Esophageal Cancer Among Asians

  2012cites this paper
• Inhibition of cyclin D1 by shRNA is associated with enhanced sensitivity to conventional therapies for head and neck squamous cell carcinoma.

  2012cites this paper